OBJECTIVES: The objective of this study was to combine urine and prostate biopsy rinse material (BRM) assays to increase sensitivity for fusion gene detection. PATIENTS AND METHODS: A total of 194 patients with suspicion of prostate cancer were prospectively included. Urine samples were collected before or after prostate biopsy, as well as BRM. RT-qPCR was used for the detection of fusion transcripts. A microfocal cancer on biopsy was defined by a single core involved with less than 3 mm of Gleason score 3 + 3 cancer. The association between RT-qPCR and biopsy results was statistically assessed. RESULTS: Seven patients were excluded because of insufficient material. Cancer was detected on biopsy in 100 (53%) patients. Urine alone, BRM alone and both samples were obtained in 155, 164 and 132 patients, respectively. In patients with evidence of cancer on biopsy, a fusion transcript was detected in 63, 55 and 73% of the cases on urine alone, BRM alone and paired samples, respectively. Fusion gene detection on BRM was only associated with the amount of cancer on biopsy. Urine fusion score had a larger area under the curve than serum PSA (p = 0.002) and was significantly higher in patients with high Gleason score and significant cancer on biopsy. Assays of paired samples allowed increasing sensitivity in all subgroups of patients. CONCLUSIONS: TMPRSS2-ERG fusion gene detection may be performed both in the urine and BRM to increase sensitivity. However, only T-E urine score was associated with adverse pathological features.
OBJECTIVES: The objective of this study was to combine urine and prostate biopsy rinse material (BRM) assays to increase sensitivity for fusion gene detection. PATIENTS AND METHODS: A total of 194 patients with suspicion of prostate cancer were prospectively included. Urine samples were collected before or after prostate biopsy, as well as BRM. RT-qPCR was used for the detection of fusion transcripts. A microfocal cancer on biopsy was defined by a single core involved with less than 3 mm of Gleason score 3 + 3 cancer. The association between RT-qPCR and biopsy results was statistically assessed. RESULTS: Seven patients were excluded because of insufficient material. Cancer was detected on biopsy in 100 (53%) patients. Urine alone, BRM alone and both samples were obtained in 155, 164 and 132 patients, respectively. In patients with evidence of cancer on biopsy, a fusion transcript was detected in 63, 55 and 73% of the cases on urine alone, BRM alone and paired samples, respectively. Fusion gene detection on BRM was only associated with the amount of cancer on biopsy. Urine fusion score had a larger area under the curve than serum PSA (p = 0.002) and was significantly higher in patients with high Gleason score and significant cancer on biopsy. Assays of paired samples allowed increasing sensitivity in all subgroups of patients. CONCLUSIONS:TMPRSS2-ERG fusion gene detection may be performed both in the urine and BRM to increase sensitivity. However, only T-E urine score was associated with adverse pathological features.
Authors: José Rubio-Briones; Antonio Fernández-Serra; Ana Calatrava; Zaida García-Casado; Luis Rubio; Miguel A Bonillo; Inmaculada Iborra; Eduardo Solsona; José A López-Guerrero Journal: J Urol Date: 2010-03-19 Impact factor: 7.450
Authors: Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou Journal: Prostate Date: 2010-09-28 Impact factor: 4.104
Authors: Giuseppe Lucarelli; Margherita Fanelli; Angela Maria Vittoria Larocca; Cinzia Annatea Germinario; Monica Rutigliano; Antonio Vavallo; Francesco Paolo Selvaggi; Carlo Bettocchi; Michele Battaglia; Pasquale Ditonno Journal: Prostate Date: 2012-03-16 Impact factor: 4.104
Authors: Jarrod P Clark; Kristofer W Munson; Jessie W Gu; Katarzyna Lamparska-Kupsik; Kevin G Chan; Jeffrey S Yoshida; Mark H Kawachi; Laura E Crocitto; Timothy G Wilson; Ziding Feng; Steven S Smith Journal: Clin Chem Date: 2008-10-23 Impact factor: 8.327
Authors: G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper Journal: Oncogene Date: 2007-07-16 Impact factor: 9.867